Targeting Histone Deacetylases: A Novel Approach in Parkinson’s Disease
The worldwide prevalence of movement disorders is increasing day by day. Parkinson’s disease (PD) is the most common movement disorder. In general, the clinical manifestations of PD result from dysfunction of the basal ganglia. Although the exact underlying mechanisms leading to neural cell death in...
Saved in:
Main Authors: | Sorabh Sharma, Rajeev Taliyan |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2015-01-01
|
Series: | Parkinson's Disease |
Online Access: | http://dx.doi.org/10.1155/2015/303294 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Acetylation and Histone Deacetylase Inhibitors in Cancer
by: Madeleine S. Q. Kortenhorst, et al.
Published: (2006-01-01) -
Histone Deacetylases Inhibitors in the Treatment of Retinal Degenerative Diseases: Overview and Perspectives
by: Hua Zhang, et al.
Published: (2015-01-01) -
Histone Deacetylase Inhibitors in Cell Pluripotency, Differentiation, and Reprogramming
by: Androniki Kretsovali, et al.
Published: (2012-01-01) -
Histone Deacetylase Inhibitors: Synthesis of Tetrapeptide Analogue SAHA/TPX
by: Lynda Ekou, et al.
Published: (2011-01-01) -
Comparison of Different Histone Deacetylase Inhibitors in Attenuating Inflammatory Pain in Rats
by: Yu Mao, et al.
Published: (2019-01-01)